Adaptive Hypersensitivity to Estrogen: Mechanism for Sequential Responses to Hormonal Therapy in Breast Cancer

Clinical Cancer Research

Volumn 10, Issue 1 II, 2004, Pages

  Santen, Richard J ^a   Song, Robert X ^a   Zhang, Zhenguo ^a   Yue, Wei ^a   Kumar, Rakesh ^b   Ingle, James ^c   Come, Steven ^c   Ellis, Matthew ^c   Green, Jeffrey ^c   Medina, Daniel ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Division of Endocrinology ^*

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AROMATASE INHIBITOR; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GESTAGEN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SHC; SOS PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR ELK 1; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR;

ADAPTATION; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CELL MEMBRANE; CELL STRUCTURE; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ESTROGEN ACTIVITY; GENE ACTIVATION; GENE CONTROL; GENETIC TRANSCRIPTION; HORMONE BINDING; HORMONE SENSITIVITY; HUMAN; HYPERSENSITIVITY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL MEMBRANE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GRB2 ADAPTOR PROTEIN; HORMONES; HUMANS; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, CONFOCAL; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROTEINS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; SON OF SEVENLESS PROTEIN, DROSOPHILA; TIME FACTORS; UP-REGULATION;

EID: 9144270449     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-031207     Document Type: Conference Paper

References (27)

1. Santen, R. J., Manni, A., Harvey, H., and Redmond, C. Endocrine treatment of breast cancer in women. Endocr. Rev., 11: 221-265, 1990.
2. Santen, R. J., and Harvey, H. A. Use of aromatase inhibitors in breast carcinoma. Endocr. Relat. Cancer, 6: 75-92, 1999.
3. Jeng, M. H., Yue, W., Eischeid, A., Wang, J. P., and Santen, R. J. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res. Treat., 62: 167-175, 2000.
4. Shim, W. S., Conaway, M., Masamura, S., Yue, W., Wang, J. P., Kmar, R., and Santen, R. J. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology, 141: 396-405, 2000.
5. Masamura, S., Santner, S. J., Heitjan, D. F., and Santen, R. J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab., 80: 2918-2925, 1995.
6. Martin, L. A., Farmer, I., Johnston, S. R., Ali, S., Marshall, C., Dowsett, M. Enhanced estrogen receptor α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J. Biol. Chem., 278: 30458-68, 2003.
7. Song, R. X., Mor, G., Naftolin, F., McPherson, R. A., Song, J., Zhang, Z., Yue, W., Wang, J., and Santen, R. J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J. Natl. Cancer Inst. (Bethesda), 93: 1714-1723, 2001.
8. Yue, W., Wang, J. P., Conaway, M., Masamura, S., and Santen, R. J. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology, 143: 3221-3229, 2002.
9. Dickson, R. B., Bates, S. E., McManaway, M. E., and Lippman, M. E. Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res., 46: t-13, 1986.
10. Joel, P. B., Smith, J., Sturgill, T. W., Fisher, T. L., Blenis, J., and Lannigan, D. A. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell. Biol., 18: 1978-1984, 1998.
11. Yue, W., Wang, J. P., Conaway, M. R., Li, Y., and Santen, R. J. Adaptive hypersensitivity following long term estrogen deprivation; involvement of multiple signaling pathways. J. Steroid Biochem. Mol. Biol., 86: 265-274, 2003.
12. Migliaccio, A., Piccolo, D., Castoria, G., Di Domenico, M., Bilancio, A., Lombardi, M., Gong, W., Beato, M., and Auricchio, F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J., 17: 2008-2018, 1998.
13. Pelicci, G., Lanfrancone, L., Salcini, A. E., Romano, A., Mele, S., Grazia, B. M., Segatto, O., Di Fiore, P. P., and Pelicci, P. G. Constitutive phosphorylation of Shc proteins in human tumors. Oncogene, 11: 899-907, 1995.
14. Dikic, I., Batzer, A. G., Blaikie, P., Obermeier, A., Ullrich, A., Schlessinger, J., and Margolis, B. Shc binding to nerve growth factor receptor is mediated by the phosphotyrosine interaction domain. J. Biol. Chem., 270: 15125-15129, 1995.
15. Song, R. X., McPherson, R. A., Adam, L., Bao, Y., Shupnik, M., Kumar, R., and Santen, R. J. Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation. Mol. Endocrinol., 16: 116-127, 2002.
16. Sato, K., Kimoto, M., Kakumoto, M., Horiuchi, D., Iwasaki, T., Tokmakov, A. A., and Fukami, Y. Adaptor protein Shc undergoes translocation and mediates up-regulation of the tyrosine kinase c-Src in EGF-stimulated A431 cells. Genes Cells, 5: 749-764, 2000.
17. Smilenov, L. B., Mikhailov, A., Pelham, R. J., Marcantonio, E. E., and Gundersen, G. G. Focal adhesion motility revealed in stationary fibroblasts. Science (Wash. DC), 286: 1172-1174, 1999.
18. Zhang, Z., Maier, B., Santen, R. J., and Song, R. X. Membrane association of estrogen receptor a mediates estrogen effect on MAPK activation. Biochem. Biophys. Res. Commun., 294: 926-933, 2002.
19. Song, R. X., Zhang Z, Boa Y, Black, M. J., and Santen, R. J. IGF-1 receptor activation and its physical interactions with adaptor protein Shc and ERα mediate the non-genomic action of estradiol in breast cancer cells. Proceedings of the 85th Annual Meeting of the Endocrine Society, Philadelphia, PA, p. 337. Endocrine Society: abst. P-2 125, 2003.
20. Santen, R. J., Endocrine-responsive cancer. In: P. R. Larsen, H. Kronenberg, S. Melmed, and K. Polonsky (eds.), Williams Textbook of Endocrinology, pp. 1797-1833. Philadelphia: W. B. Saunders, 2003.
21. Elad-Sfadia, G., Haklai, R., Ballan, E., Gabius, H. J., and Kloog, Y. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J. Biol. Chem., 277: 37169-37175, 2002.
22. McPherson, R. A., Conaway, M. C., Gregory, C. W., Yue, W., and Santen, R. J. The novel ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. The Prostate, 9999: 1-10, 2003 (early view).
23. Song, R. X., Berstein, L., and Santen, R. J. Response: Re: effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. J. Natl. Cancer Inst. (Bethesda), 94: 1173-1174, 2002.
24. Jordan, V. C., Liu, H., and Dardes, R. Re: effect of long-term estroger deprivation on apoptotic responses of breast cancer cells to 17β-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. J. Natl. Cancer Inst. (Bethesda), 94: 1173, 2002.
25. Soto, A. M., and Sonnenschein, C. Response: Re: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. J. Natl. Cancer Inst. (Bethesda), 94: 1174-1175, 2002.
26. Soto, A. M., and Sonnenschein, C. The two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. J. Natl. Cancer Inst. (Bethesda), 93: 1673-1675, 2001.
27. Ingle, J. N. Estrogen as therapy for breast cancer. Breast Cancer Res., 4: 133-136, 2002.